share_log

Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $57

Benzinga ·  Apr 17 12:26

Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target from $67 to $57.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment